Decoy Therapeutics Inc.
DCOYNASDAQHealthcareBiotechnology
Previous close
$3.20
−$0.08 · -2.44%
DCOY company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
46
Fair Value
Momentum
22
Weakening
Sentiment
50
Mixed
Risk resilience
35
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteBased in Cambridge, Massachusetts, Decoy Therapeutics Inc. is an early-stage biotechnology firm dedicated to tackling critical unmet medical needs. The company employs cutting-edge machine learning and AI technologies, alongside accelerated synthesis methods, to swiftly design, engineer, and manufacture innovative peptide conjugate drug candidates.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Frederick E. Pierce
- Listed since
- Jan 29, 2015
- Employees
- 11
Market position
Day range
Current $3.20
52-week range
Current $3.20
- Open
- $3.29
- Previous close
- $3.28
- Volume
- 15.21K
- 0.08× average
- Average volume
- 180.7K
- Average daily volume
- Market cap
- 1.7M USD
- Beta
- 0.58
- Market reference 1
- 50-day average
- $5.2081
- -38.56% below average
- 200-day average
- $7.9624
- -59.81% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- -6.96M USD
- P/E (TTM)
- -0.11×
- P/B (TTM)
- 0.39×
- P/S (TTM)
- 0×
- EV / EBITDA
- 0.56×
- Earnings yield
- -333.69%
- Free cash flow yield
- -128.67%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -212.58%
- Return on assets
- -113.22%
- Return on invested capital
- -214.20%
Financial health
- Debt / equity
- 0×
- Current ratio
- 2.13×
- Altman Z-score
- -19.96
- Piotroski F-score
- 2 of 9
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 8.52M USD | — | — | — | — |
| Gross profit | −8.52M USD | — | — | — | — |
| Research and development | 368.17K USD | 770.03K USD | 7.17M USD | 15.84M USD | 8.55M USD |
| Selling, general, and administrative | 3.73M USD | 4.96M USD | 5.72M USD | 7.14M USD | 6.1M USD |
| Operating expenses | 4.1M USD | 5.73M USD | 12.89M USD | 31.84M USD | 12.81M USD |
| Interest income | 95.47K USD | 158.54K USD | 352.25K USD | 218.73 USD | — |
| Depreciation and amortization | 7.15K USD | 4.42K USD | 10.05K USD | 6.68K USD | 19.18K USD |
| Operating income | −12.61M USD | −5.73M USD | −12.89M USD | −31.84M USD | −12.81M USD |
| Net income | −12.52M USD | −5.58M USD | −12.54M USD | −31.61M USD | −12.77M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 73%
- 8 beats, 3 misses, 0 met estimates
- Average EPS surprise
- +44.95%
- 11 comparable reports
- Latest EPS result
- -4.46
- Estimate -2.88 · Miss by 54.86%
EPS: actual versus estimate
Recent quarterly results
DCOY news
DCOY peers
ETFs holding DCOY
Funds reporting this stock among their holdings, ordered by reported position size.
Continue in GoAI
Research DCOYresearch.disclaimer